Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programmes-from the municipality level to the EU level-were launched, resulting in an overall decrease in viremic HCV infections and liver-related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID-19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct-acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost-saving than treating and caring for patients with liver-related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale-up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the third EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and reported the 'Call-to-Action' statement supported by all the major relevant European associations in the field.

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.15446DOI Listing

Publication Analysis

Top Keywords

hcv elimination
20
hcv
11
securing wider
8
wider commitment
8
hepatitis virus
8
chronic hcv
8
hcv infection
8
elimination
7
commitment elimination
4
elimination hepatitis
4

Similar Publications

Aim Of The Study: To analyze long-term epidemiological patterns and trends in the burden of infection and mortality due to viral hepatitis in Poland before and during the COVID-19 pandemic.

Material And Methods: Data for the burden of the most common viral hepatitis types (HAV, HBV ±HDV, HCV, and HEV) over 2009-2023 were extracted from the national registries in Poland. The joinpoint regression model was used to analyze trends in viral hepatitis infections and mortality.

View Article and Find Full Text PDF

Hepatitis C virus microelimination among men who have sex with men in Taiwan: Our progress, achievements, and remaining challenges.

J Formos Med Assoc

September 2025

Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan

Since 2010, high-risk sexual contact has become a major route of hepatitis C virus (HCV) transmission in Taiwan, particularly among men who have sex with men (MSM). With the rollout of direct-acting antivirals (DAAs) and the implementation of national strategies such as mass screening and reflex viral load testing to improve detection of HCV viremia, Taiwan has made substantial progress toward HCV elimination. Among MSM living with HIV, the prevalence, incidence, and reinfection rates of HCV have significantly declined following the implementation of the HCV elimination program.

View Article and Find Full Text PDF

Background HIV and Hepatitis C (HCV) are blood borne infections (BBIs) that remain a significant cause of global morbidity and mortality among people who inject drugs (PWID). UNAIDS and WHO have set goals for the elimination of viral hepatitis and HIV as major public health threats by 2030. To achieve these targets, innovative strategies are required among marginalized populations such as PWID, especially in resource-limited countries where coverage of harm reduction services is often limited.

View Article and Find Full Text PDF

Background: People with human immunodeficiency virus (HIV; PWH) are at increased risk of hepatitis C virus (HCV) coinfection and experiencing negative clinical outcomes. We evaluated direct-acting antiviral (DAA) initiation among PWH with HCV to identify factors associated with initiation.

Methods: US and Canadian PWH ≥18 years with a detectable HCV RNA in the North American AIDS Cohort Collaboration on Research and Design were followed up from the latest of first detectable HCV viremia, antiretroviral therapy initiation, enrollment date, or 1 January 2014 until the first of DAA prescription, clearance of HCV viremia, loss to follow-up, death, or 31 December 2021.

View Article and Find Full Text PDF

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are sexually transmitted and blood-borne infections that Canada is committed to eliminate as public health concerns. Accurate epidemiological estimates require cross-sectional data as input. The objective of this study was to estimate the prevalence of present HBV infection (hepatitis B surface antigen-positive) and proportion aware of their infection, the vaccine-induced HBV immunity, the prevalence of HCV antibodies (anti-HCV-positive), the prevalence of present HCV infection (RNA-positive) and proportion aware of their infection, in the household population in Canada.

View Article and Find Full Text PDF